Bookmarks
CORYLUS UK: A retrospective observational cohort study of the impact of COVID-19 on systemic lupus erythematosus patients in England using data from linked primary and secondary care databases
Safe People
Organisation name
Health IQ
Organisation sector
Commercial
Applicant name(s)
Jay Were - Chief Investigator - Health iQShea O'Connell - Corresponding Applicant - Health iQArchie Farrer - Collaborator - Health iQBoglarka Kovacs - Collaborator - Health iQGulsah Akin Unal - Collaborator - Health iQJudith Ruzangi - Collaborator - Health iQMico Hamlyn - Collaborator - Health iQ
Safe Projects
Project ID
CPRD696
Lay summary
Systemic lupus erythematosus (SLE) is a complicated and chronic autoimmune disease where a patient’s own immune system can attack any part of their body. SLE has a huge range of symptoms from rash and hair loss, through to heart disease and serious brain and nerve problems from constant immune activity. Commonly prescribed medications include steroids and immunosuppressants that leave patients in an immunocompromised state, depending on the severity of their disease and medication dosage.
Technical summary
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by autoantibodies, systemic inflammation and lymphopenia. There is no cure for SLE, and treatment depends on severity, including non-steroidal anti-inflammatories (NSAIDs), corticosteroids, immunosuppressants, and antimalarial agents such as chloroquine or hydroxychloroquine. Whilst corticosteroids are rapidly effective for suppressing flares, long term use has considerable side-effects[1].
Latest approval date
09/03/2021
Safe Data
Dataset(s) name
HES Accident and Emergency
HES Admitted Patient Care
HES Outpatient
ONS Death Registration Data
Safe Setting
Access type
Release